With Increased Revenues, Decreased Costs, Lynx Considering Various Options | GenomeWeb

NEW YORK, Aug. 13 (GenomeWeb News) - Lynx Therapeutics of Hayward, Calif., reported increased revenues and slashed its net loss nearly in half, but with $3 million in cash and cash equivalents, including restricted cash, on hand, the company is "considering various other options, including additional equity financing," Kevin Corcoran, the company president and CEO said in a statement today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.